Short Interest in KALA BIO, Inc. (NASDAQ:KALA) Rises By 19.1%

KALA BIO, Inc. (NASDAQ:KALA - Get Free Report) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 25,600 shares, a growth of 19.1% from the December 31st total of 21,500 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 34,800 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of KALA BIO in a research report on Friday, November 15th.

KALA BIO Stock Up 4.3 %

Shares of NASDAQ:KALA traded up $0.40 during midday trading on Wednesday, hitting $9.70. 77,623 shares of the stock were exchanged, compared to its average volume of 67,462. The company has a market capitalization of $59.07 million, a PE ratio of -0.78 and a beta of -2.04. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. KALA BIO has a 52-week low of $4.21 and a 52-week high of $9.80. The business's fifty day simple moving average is $7.17 and its two-hundred day simple moving average is $6.50.

KALA BIO (NASDAQ:KALA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($1.93) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.43) by $0.50. As a group, research analysts predict that KALA BIO will post -10.84 earnings per share for the current fiscal year.

Insider Buying and Selling at KALA BIO

In related news, CEO Mark T. Iwicki sold 5,779 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $7.63, for a total value of $44,093.77. Following the completion of the transaction, the chief executive officer now owns 280,076 shares of the company's stock, valued at approximately $2,136,979.88. This trade represents a 2.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Bros. Advisors Lp Baker bought 310,559 shares of the business's stock in a transaction on Monday, December 30th. The shares were purchased at an average cost of $6.44 per share, for a total transaction of $1,999,999.96. Following the completion of the purchase, the insider now owns 1,083,398 shares in the company, valued at approximately $6,977,083.12. This trade represents a 40.18 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 9,506 shares of company stock valued at $72,531. Corporate insiders own 8.32% of the company's stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.